An observational study in Covid19, sponsored by Kyungpook National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Kyungpook National University Hospital · Observational
Among 89 studies in COVID-19 with a site in Korea, Republic of — 10 open to participants now, 18 under way, 6 of them phase 3. COVID-19 · Korea, Republic of.
Among the 89 studies in COVID-19 with a site in Korea, Republic of, this one is the 16th largest by planned enrollment of the 18 observational ones that give a count, is one of 29 that started in 2021, is one of 18 observational ones, reaches primary completion later than 1 of the 17 other live ones, and was the 47th registered.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
Browse COVID-19 studies →10 of the 89 studies in COVID-19 with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Pfizer · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 21 more countries
Jaehoon Ko · Sites in Korea, Republic of
Pfizer · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 356 COVID-19 studies recruiting now, 207 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 136 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 30 · Phase 3 30 · Phase 4 2
First in 2018; this study’s year is marked. 29 started in 2021.
This study's planned enrollment of 51 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Median enrollment 260 across the 71 interventional studies, 730 across the 18 observational. Of the 58 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 89 have an industry lead sponsor. The 10 most frequent:
Kyungpook National University Hospital is the lead sponsor of 80 studies on the registry; 8 are open to participants now.
Kyungpook National University Hospital has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
6 of the studies in COVID-19 with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
Among the 89 studies in COVID-19 with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
healthcare works aged 20-60 years after completion of COVID-19 vaccination
participants have no serious disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study enrolled persons already who received COVID-19 vaccination under government policy. 1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination 2. isolate serum and store in -80 degree deep freezer 3. measure neutralizing Antibody
titer of neutralizing antibody after COVID-19 vaccination
semi-quantitative measurement of neutralizing antibody after COVID-19 vaccination
Time frame: at 2month after COVID-19 vaccination
titer of neutralizing antibody after COVID-19 vaccination
semi-quantitative measurement of neutralizing antibody after COVID-19 vaccination
Time frame: at 4 month after COVID-19 vaccination
titer of neutralizing antibody after COVID-19 vaccination
semi-quantitative measurement of neutralizing antibody after COVID-19 vaccination
Time frame: at 6 month after COVID-19 vaccination
titer of neutralizing antibody after COVID-19 vaccination
semi-quantitative measurement of neutralizing antibody after COVID-19 vaccination
Time frame: at 9 month after COVID-19 vaccination
titer of neutralizing antibody after COVID-19 vaccination
semi-quantitative measurement of neutralizing antibody after COVID-19 vaccination
Time frame: at 12 month after COVID-19 vaccination
body weight (Kg)
correlation between antibody titer and body weight: spearmann's correlation
Time frame: at 2 month after COVID-19 vaccination
body mass index (kg/m^2)
correlation between antibody titer and body weight: spearmann's correlation
Time frame: at 2 month after COVID-19 vaccination
Compare 4 diagnostic ELISA kit after COVID-19 vaccination
1. measure neutralizung antibody using ELISA kits from 4 different companies 2 months after COVID-19 vaccination 2. investigate correlation coefficient of antibody titer between companies
Time frame: at 2 month after COVID-19 vaccination
Plan to share: No
Started Jun 2021 (actual). Primary completion is estimated for Dec 2024, 42 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 42 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kyungpook National University Hospital